Insights
Events & CLE
MedInvest Biotech and Pharma Investor Conference

MedInvest Biotech and Pharma Investor Conference

September 18, 2024

O’Melveny partners Nate Gallon, Dr. Geoff Kuziemko, and David Ribner will be guest speakers at the 2024 MedInvest Conference. This year, the National Institutes of Health and O’Melveny are the Presenting Partners. The two-day event will feature “leading life sciences and healthcare venture capitalists, family offices, lawyers, pharma executives, private and public biotech and pharmaceuticals companies and foundations for a discussion on trends, opportunities, and risks in life science investing.”

Nate Gallon has spent his entire legal career in Silicon Valley counseling his clients on corporate and securities law and also acts more generally as a trusted business advisor in connection with a wide range of transactions that technology companies typically undertake throughout their life cycle – entity formation, debt and equity financings, recapitalizations, joint ventures, spin-offs, and growth stage through to a liquidity event.

Dr. Geoff Kuziemko focuses his practice on assisting clients, primarily in the life sciences sector, with intellectual property and technology-intense transactions. His work runs the gamut of complex transactions, from out-bound license and in-bound license, development, commercialization, strategic alliance and joint venture, collaboration, and profit-sharing agreements to commercial agreements for distribution, manufacture, and supply, as well as intellectual property due diligence for strategic acquisitions and financings involving life sciences businesses, products, and patents.

David Ribner has extensive experience securing national security clearance by the Committee on Foreign Investment in the United States (CFIUS), having served as CFIUS counsel in transactions with investors spanning the globe and myriad industries. He counsels clients on compliance with US economic sanctions, export controls, customs laws, and antiboycott regulations, as well as the Foreign Corrupt Practices Act (FCPA), and advises on the development and implementation of related corporate compliance programs.